Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) traded down 1.4% on Thursday . The stock traded as low as $61.57 and last traded at $61.91, with a volume of 272,737 shares trading hands. The stock had previously closed at $62.82.

Several equities research analysts have weighed in on the stock. Chardan Capital restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, July 11th. JMP Securities restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Sunday, July 10th. Cowen and Company restated a “buy” rating and issued a $150.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Tuesday, July 5th. FBR & Co restated an “outperform” rating and issued a $180.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Tuesday, July 5th. Finally, Zacks Investment Research upgraded shares of Alnylam Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 5th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $117.82.

The firm has a 50-day moving average of $62.13 and a 200-day moving average of $65.17. The stock’s market cap is $5.52 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Monday, May 2nd. The biopharmaceutical company reported ($1.21) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.05) by $0.16. The company earned $7.30 million during the quarter, compared to analysts’ expectations of $7.79 million. The business’s revenue was down 60.4% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.62) earnings per share. On average, equities research analysts forecast that Alnylam Pharmaceuticals Inc. will post ($4.94) earnings per share for the current fiscal year.

In related news, CEO John Maraganore sold 30,151 shares of the firm’s stock in a transaction that occurred on Wednesday, April 20th. The stock was sold at an average price of $67.46, for a total transaction of $2,033,986.46. Following the completion of the sale, the chief executive officer now directly owns 148,465 shares of the company’s stock, valued at approximately $10,015,448.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Other hedge funds and institutional investors have recently added to or reduced their stakes in the company. Jennison Associates LLC increased its position in Alnylam Pharmaceuticals by 0.5% in the fourth quarter. Jennison Associates LLC now owns 1,489,541 shares of the biopharmaceutical company’s stock valued at $140,225,000 after buying an additional 7,296 shares during the last quarter. Advisors Asset Management Inc. increased its position in Alnylam Pharmaceuticals by 0.3% in the fourth quarter. Advisors Asset Management Inc. now owns 64,827 shares of the biopharmaceutical company’s stock valued at $6,103,000 after buying an additional 226 shares during the last quarter. Mutual of America Capital Management LLC increased its position in Alnylam Pharmaceuticals by 0.4% in the fourth quarter. Mutual of America Capital Management LLC now owns 21,637 shares of the biopharmaceutical company’s stock valued at $2,037,000 after buying an additional 87 shares during the last quarter. Gulf International Bank UK Ltd increased its position in Alnylam Pharmaceuticals by 1.0% in the fourth quarter. Gulf International Bank UK Ltd now owns 23,100 shares of the biopharmaceutical company’s stock valued at $2,175,000 after buying an additional 220 shares during the last quarter. Finally, Baillie Gifford & Co. increased its position in Alnylam Pharmaceuticals by 284.6% in the fourth quarter. Baillie Gifford & Co. now owns 2,727,734 shares of the biopharmaceutical company’s stock valued at $256,790,000 after buying an additional 2,018,484 shares during the last quarter.

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.